Stockscreener 앱 받기
1.2499
2.59%
0.0399
전일 마감가:
$1.21
열려 있는:
$1.22
하루 거래량:
20,718
Relative Volume:
0.14
시가총액:
$85.90M
수익:
-
순이익/손실:
$-9.22M
주가수익비율:
-4.2849
EPS:
-0.2917
순현금흐름:
$-4.60M
1주 성능:
+7.01%
1개월 성능:
-3.02%
6개월 성능:
+8.89%
1년 성능:
-36.67%
1일 변동 폭
$1.21
$1.25
1주일 범위
$1.06
$1.25
52주 변동 폭
$0.8885
$2.091
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
명칭
Telomir Pharmaceuticals Inc
전화
786-396-6723
주소
100 SE 2ND ST, MIAMI
Compare TELO vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.249 | 84.59M | 0 | -9.22M | -4.60M | -0.2917 |
VRTX
Vertex Pharmaceuticals Inc
|
475.39 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
706.27 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.90 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.93 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
319.04 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-21 | 개시 | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc 주식(TELO)의 최신 뉴스
Telomir Pharmaceuticals (TELO) awards director 50,000 stock options at $1.34 - Stock Titan
Telomir Pharmaceuticals Inc (TELO) Valuation: PE, PB & Fair Value Analysis - TradingKey
TELO|Telomir Pharmaceuticals Inc|Price:1.230|Chg%:+0.080 - TradingKey
Telomir Pharmaceuticals Inc (TELO) Institutional Confidence - TradingKey
Telomir Pharmaceuticals Inc (TELO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Telomir Pharmaceuticals Inc (TELO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Telomir Pharmaceuticals Inc (TELO) Cash Flow - TradingKey
Telomir Pharmaceuticals Inc (TELO) Balance Sheet - TradingKey
Telomir Pharmaceuticals Inc (TELO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Telomir Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals Inc (TELO) Income Statement - TradingKey
Telomir Pharmaceuticals Inc (TELO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
12 Health Care Stocks Moving In Tuesday's Intraday Session - Sahm
Andriy Mushak Net Worth (2026) - GuruFocus
TELO Q4 2025 Earnings: EPS Misses Estimates by Wide Margin as Pre-Revenue Biotech Reports No RevenueEarnings Power Value - DonanımHaber
Number of shareholders of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals (TELO) Slips 2.3% as Stock Tests Key Support LevelBullish Percent Index - dars.gov.et
Price to earnings forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:TELO) - TradingView
TELO Q4 2025 Earnings: Wider-Than-Expected Loss Reflects R&D InvestmentWeak Earnings Momentum - DonanımHaber
Price to sales forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Price to book forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Enterprise value to EBITDA forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals Inc (TELO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Telomir Pharmaceuticals, Inc. develops Telomir-Zn to target intracellular metal balance in cancer cells - Traders Union
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model - ACCESS Newswire
Telomir Pharmaceuticals Q4 2025 Earnings: EPS Misses Estimates Amid Pre-Revenue Development StageEarnings Sentiment Score - DonanımHaber
Telomir Pharmaceuticals Inc (TELO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Telomir Pharmaceuticals to advance Telomir-Zn into clinical development for triple-negative breast cancer - Traders Union
Telomir Pharmaceuticals, Inc.: Telomir-Zn reverses insulin resistance in 14 days in new study - Traders Union
Exclusive: Telomir Pharmaceuticals secures FDA nod for its breast cancer therapy to advance into human study - MSN
Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data - TipRanks
Telomir publishes preclinical data on diabetes treatment candidate By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Publishes Peer-Reviewed Data Showing Telomir-Zn Restores Insulin Sensitivity in Type 2 Diabetes Model – Minichart - Minichart
Telomir publishes preclinical data on diabetes treatment candidate - Investing.com
Telomir (NASDAQ: TELO) adds Telomir-Zn diabetes data to support FDA-cleared TNBC trial - Stock Titan
Experimental drug candidate reversed insulin resistance in 14 days — in fish - Stock Titan
Telomir Pharmaceuticals (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Pre‑Revenue Development StageSubscription Growth Report - newsline.com
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Despite Positive Stock Reaction - newsline.com
Telomir Pharmaceuticals, Inc. reveals promising anti-tumor impact with Telomir-Zn in prostate cancer study - Traders Union
Telomir Pharmaceuticals (TELO) CFO Andriy Mushak files initial Form 3 - Stock Titan
Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO - Investing.com UK
Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change - TipRanks
Telomir Pharmaceuticals appoints Andriy Mushak as fractional CFO By Investing.com - Investing.com Australia
Telomir PharmaceuticalsAlan Weichselbaum To Step Down As CFO Effective June 6, 2026SEC Filing - TradingView
Telomir Pharmaceuticals, Inc. Announces CFO Changes, Effective June 6, 2026 - marketscreener.com
Telomir Pharmaceuticals (NASDAQ: TELO) taps consultant as new fractional CFO - Stock Titan
Telomir Pharmaceuticals (TELO) Edges Lower Amid Consolidation Near SupportTrend Following Picks - newsline.com
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer - ACCESS Newswire
Telomir Pharmaceuticals Inc (TELO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
1.17%
자본화:
|
볼륨(24시간):